Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

8.240 +0.070 (+0.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in BTIG Fireside Discussion
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces $26.5 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present at the LD Micro Investor Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023
From Coya Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.